Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells

To initiate SARS-CoV-2 infection, the Receptor Binding Domain (RBD) on the viral spike protein must first bind to the host receptor ACE2 protein on pulmonary and other ACE2-expressing cells. We hypothesized that cardiac glycoside drugs might block the binding reaction between ACE2 and the Spike (S)...

Descripción completa

Detalles Bibliográficos
Autores principales: Caohuy, Hung, Eidelman, Ofer, Chen, Tinghua, Liu, Shufeng, Yang, Qingfeng, Bera, Alakesh, Walton, Nathan I., Wang, Tony T., Pollard, Harvey B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589851/
https://www.ncbi.nlm.nih.gov/pubmed/34773067
http://dx.doi.org/10.1038/s41598-021-01690-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589851/
https://www.ncbi.nlm.nih.gov/pubmed/34773067
http://dx.doi.org/10.1038/s41598-021-01690-9

Ejemplares similares